Altimmune Inc (NASDAQ:ALT) has a beta value of 1.17 and has seen 0.55 million shares traded in the recent trading session. The company, currently valued at $366.97M, closed the recent trade at $4.76 per share which meant it gained $0.21 on the day or 4.73% during that session. The ALT stock price is -134.45% off its 52-week high price of $11.16 and 25.42% above the 52-week low of $3.55. If we look at the company’s 10-day average daily trading volume, we find that it stood at 2.36 million shares traded. The 3-month trading volume is 2.49 million shares.
The consensus among analysts is that Altimmune Inc (ALT) is Buy stock at the moment, with a recommendation rating of 1.20. 0 analysts rate the stock as a Sell, while 0 rate it as Overweight. 0 out of 6 have rated it as a Hold, with 6 advising it as a Buy. 0 have rated the stock as Underweight. The expected earnings per share for the stock is -0.34.
Altimmune Inc (NASDAQ:ALT) trade information
Sporting 4.73% in the green today, the stock has traded in the green over the last five days, with the highest price hit on recent trading when the ALT stock price touched $4.76 or saw a fall of -0.21%. Year-to-date, Altimmune Inc shares have moved -33.91%, while the 5-day performance has seen it change 8.05%. Over the past 30 days, the shares of Altimmune Inc (NASDAQ:ALT) have changed -17.56%. Short interest in the company has seen 21.82 million shares shorted with days to cover at 7.14.
Wall Street analysts have a consensus price target for the stock at $25, which means that the shares’ value could jump 80.96% from the levels at last check today.. The projected low price target is $12.0 while the price target rests at a high of $35.0. In that case, then, we find that the latest price level in today’s session is -635.29% off the targeted high while a plunge would see the stock gain -152.1% from the levels at last check today..
Altimmune Inc (ALT) estimates and forecasts
The company’s shares have lost -30.54% over the past 6 months. Revenue growth from the last financial year stood is estimated to be 111,022.20%.
9 analysts offering their estimates for the company have set an average revenue estimate of 560 for the current quarter. 9 have an estimated revenue figure of 560 for the next ending quarter. Year-ago sales stood 5k and 5k respectively for this quarter and the next, and analysts expect sales will shrink by -88.80% for the current quarter and 111,022.20% for the next.
If we evaluate the company’s growth over the last 5-year and for the next 5-year period, we find that annual earnings growth was 3.48% over the past 5 years. Earnings growth for 2025 is a modest -6.99% while over the next 5 years, the company’s earnings are expected to increase by 0.77%.
ALT Dividends
Altimmune Inc is expected to release its next earnings report on 2025-Feb-26 this year, and investors are excited at the prospect of better dividends despite the company’s debt issue.
Altimmune Inc (NASDAQ:ALT)’s Major holders
Insiders own 0.80% of the company shares, while shares held by institutions stand at 53.81% with a share float percentage of 54.24%. Investors are also buoyed by the number of investors in a company, with Altimmune Inc having a total of 250.0 institutions that hold shares in the company. The top two institutional holders are BLACKROCK INC. with over 5.32 million shares worth more than $35.39 million. As of 2024-06-30, BLACKROCK INC. held 7.5025% of shares outstanding.
The other major institutional holder is VANGUARD GROUP INC, with the holding of over 4.91 million shares as of 2024-06-30. The firm’s total holdings are worth over $32.63 million and represent 6.9301% of shares outstanding.
Also the top two Mutual Funds that are holding company’s shares are VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund and iShares Trust-iShares Russell 2000 ETF . As of Dec 31, 2024 , the former fund manager holds about 2.90% shares in the company for having 2.24 shares of worth $10.65 million while later fund manager owns 1.91 shares of worth $9.11 million as of Mar 31, 2025 , which makes it owner of about 2.49% of company’s outstanding stock.
